Related Experiment Video

Updated: Jun 16, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Targeted therapeutic approaches for hormone-refractory prostate cancer

Flora Stavridi1, Eleni M Karapanagiotou, Kostas N Syrigos

  • 1Department of Medicine, Royal Marsden Hospital, Downs Road, Surrey, UK. florastavridi@yahoo.co.uk

Cancer Treatment Reviews
|January 29, 2010
PubMed

Insights

Novel treatments are being investigated to improve survival for men with advanced prostate cancer (HRPC). These therapies target specific pathways and combine new drugs with chemotherapy for better outcomes.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Prostate cancer is a leading cause of cancer death in men, often incurable in the metastatic stage.
  • Hormone-refractory prostate cancer (HRPC) progresses despite initial androgen deprivation due to genetic alterations.
  • Docetaxel offers a limited survival benefit for HRPC, necessitating improved therapeutic strategies.

Purpose of the Study:

  • To review the latest clinical evidence on novel agents for metastatic hormone-refractory prostate cancer (HRPC).
  • To explore emerging therapeutic strategies targeting specific pathways involved in prostate cancer progression.
  • To discuss the potential of multidisciplinary approaches combining novel drugs, immunotherapy, and chemotherapy.

Main Methods:

  • Review of current clinical trials and evidence regarding novel agents in HRPC.
  • Investigation of drugs targeting cell signaling, proliferation, angiogenesis, apoptosis, and immune modulation.
  • Analysis of combinations of novel agents with cytotoxic drugs and immunotherapies.

Main Results:

  • Several novel drugs targeting specific pathways are under investigation as single agents or in combination therapy.
  • Clinical trials are evaluating vitamin D receptor agonists, angiogenesis inhibitors, and EGFR blockers.
  • Immunomodulatory agents and vaccines have reached advanced clinical trial phases (Phase III).

Conclusions:

  • New drugs targeting the bone microenvironment, apoptosis, and proliferation pathways show promise in enhancing chemotherapy efficacy.
  • Multidisciplinary approaches are crucial for future therapeutic strategies in HRPC.
  • Exploiting novel molecular targets in conjunction with immunotherapy and chemotherapy is key to improving outcomes for HRPC patients.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...